A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Major Depressive Disorder

In brief

X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)

Key facts

Study ID
NCT07076407
Run by
Xenon Pharmaceuticals Inc.
People needed
450
Starts
2025-07-08
Expected to finish
2027-07-01
Last updated by the study team
2026-08-03

Who can join

Age: 18 and older, up to 74. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.